A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)

V. Lee; M. Zahurak; A. Cercek; H. Verheul; H. Lenz; P. Jones; S. Baylin; R. Parkinson; V. Rami; E. Lilly; T. Miles; T. Brown; N. Ahuja; A. El Khoueiry; N. Azad

doi:https://doi.org/10.1016/S0959-8049(20)31096-0

A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)

V. Lee, M. Zahurak, A. Cercek, H. Verheul, H. Lenz, P. Jones, S. Baylin, R. Parkinson, V. Rami, E. Lilly, T. Miles, T. Brown, N. Ahuja, A. El Khoueiry, N. Azad

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	S12
Journal	European Journal of Cancer
Volume	138
DOIs	https://doi.org/10.1016/S0959-8049(20)31096-0
Publication status	Published - Oct 2020

Access to Document

https://doi.org/10.1016/S0959-8049(20)31096-0

Cite this

Lee, V., Zahurak, M., Cercek, A., Verheul, H., Lenz, H., Jones, P., Baylin, S., Parkinson, R., Rami, V., Lilly, E., Miles, T., Brown, T., Ahuja, N., El Khoueiry, A., & Azad, N. (2020). A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts). European Journal of Cancer, 138, S12. https://doi.org/10.1016/S0959-8049(20)31096-0

@article{fb8adcd63f4a4ccea74c679cc860ab41,

title = "A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)",

author = "V. Lee and M. Zahurak and A. Cercek and H. Verheul and H. Lenz and P. Jones and S. Baylin and R. Parkinson and V. Rami and E. Lilly and T. Miles and T. Brown and N. Ahuja and {El Khoueiry}, A. and N. Azad",

year = "2020",

month = oct,

doi = "https://doi.org/10.1016/S0959-8049(20)31096-0",

language = "English",

volume = "138",

pages = "S12",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

Lee, V, Zahurak, M, Cercek, A, Verheul, H, Lenz, H, Jones, P, Baylin, S, Parkinson, R, Rami, V, Lilly, E, Miles, T, Brown, T, Ahuja, N, El Khoueiry, A & Azad, N 2020, 'A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)', European Journal of Cancer, vol. 138, pp. S12. https://doi.org/10.1016/S0959-8049(20)31096-0

TY - JOUR

T1 - A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)

AU - Lee, V.

AU - Zahurak, M.

AU - Cercek, A.

AU - Verheul, H.

AU - Lenz, H.

AU - Jones, P.

AU - Baylin, S.

AU - Parkinson, R.

AU - Rami, V.

AU - Lilly, E.

AU - Miles, T.

AU - Brown, T.

AU - Ahuja, N.

AU - El Khoueiry, A.

AU - Azad, N.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85093929815&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S0959-8049(20)31096-0

DO - https://doi.org/10.1016/S0959-8049(20)31096-0

M3 - Article

SN - 0959-8049

VL - 138

SP - S12

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)

Access to Document

Other files and links

Cite this